ROCHE's PURCHASE OF SYNTEX WILL NOT AFFECT ALEVE
This article was originally published in The Tan Sheet
ROCHE's PURCHASE OF SYNTEX WILL NOT AFFECT ALEVE, P&G said in response to the announcement that Hoffmann-La Roche has signed an agreement to acquire Syntex. A Procter & Gamble spokesperson said the company plans to begin shipping the new naproxen sodium-based OTC analgesic "over the next few weeks" under a development and marketing joint venture arrangement with Syntex. The P&G/Syntex joint venture also markets the analgesic Percogesic and has options to develop future Rx-to-OTC switches.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC